The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age.
 
Kevin Kalinsky
Employment - EQRx (I)
Stock and Other Ownership Interests - EQRx (I)
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; Mersana; mersana; Myovant Sciences; Novartis; Pfizer; Prelude Therapeutics; ProteinQure; Puma Biotechnology; RayzeBio; Regor; Relay Therapeutics; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Mattea Reinisch
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Pfizer; Roche Pharma AG; Seagen; SOMATEX; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Seagen; Somatex
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Roche Pharma AG; Stemline Therapeutics
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Marc Debled
No Relationships to Disclose
 
Binghe Xu
Consulting or Advisory Role - AstraZeneca; Novartis
 
Lowell Hart
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
 
Stephanie Graff
Stock and Other Ownership Interests - HCA Healthcare
Honoraria - Wolters Kluwer
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Menarini; Novartis; Pfizer
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst)
Other Relationship - Dr. Susan Love Foundation for Breast Cancer Research
(OPTIONAL) Uncompensated Relationships - The Dempsey Center
 
Qiang Liu
No Relationships to Disclose
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca; AstraZeneca (Inst); Baxter (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); CD Pharma (Inst); ClinSol; Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medac (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst); Stemline Therapeutics
 
Sherene Loi
Honoraria - Adanate; Amaroq Therapeutics; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Domain Therapeutics; Exact Sciences; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Roche/Genentech; SAGA Diagnostics
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - BMS
Other Relationship - Roche Medical writing support
 
Priyanka Sharma
Stock and Other Ownership Interests - Amgen; Gilead Sciences (I); Johnson & Johnson/Janssen; Pfizer (I); Roche/Genentech (I); Sanofi
Consulting or Advisory Role - AstraZeneca; Boston Scientific (I); Cipla (I); Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Salient Pharmaceuticals (I); Sanofi; Stemline Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Viktoriya Sakalosh
Employment - Translation Research in Oncology
Research Funding - Novartis (Inst)
 
Melissa Gao
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Elizabeth Santarsiero
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sorcha Waters
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Shaheen Islam
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche